Jump to ContentJump to Main Navigation
Show Summary Details

Clinical Chemistry and Laboratory Medicine (CCLM)

Published in Association with the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM)

Editor-in-Chief: Plebani, Mario

Ed. by Gillery, Philippe / Lackner, Karl J. / Lippi, Giuseppe / Melichar, Bohuslav / Payne, Deborah A. / Schlattmann, Peter / Tate, Jillian R.

IMPACT FACTOR increased in 2015: 3.017
Rank 5 out of 30 in category Medical Laboratory Technology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2015: 0.873
Source Normalized Impact per Paper (SNIP) 2015: 0.982
Impact per Publication (IPP) 2015: 2.238

See all formats and pricing


Select Volume and Issue


Changes of matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs) in the serum of patients with autoimmune diseases: association with age and disease activity

Nikoleta Ziouti1 / Demitrios H. Vynios2 / Alexios J. Aletras3 / Dora Kyriakopoulou4 / Anna Mastorakou5 / Andreas Andonopoulos6







Corresponding author: Demitrios H. Vynios, Laboratory of Biochemistry, Department of Chemistry, University of Patras, 26500 Patras, Greece. Phone: +30-2610-997876, Fax: +30-2610-997154, E-mail:

Citation Information: Clinical Chemistry and Laboratory Medicine. Volume 42, Issue 8, Pages 880–888, ISSN (Print) 1434-6621, DOI: https://doi.org/10.1515/CCLM.2004.143, June 2005

Publication History

March 8, 2004
May 10, 2004
Published Online:


Matrix metalloproteinases participate in the degradation of the extracellular matrix proteins and are regulated mainly by their respective tissue inhibitors. In a variety of inflammatory connective tissue diseases, variations in the tissue content of both metalloproteinases and tissue inhibitors have been reported. The purpose of this study was to determine the serum levels of metalloproteinases and tissue inhibitors in patients with autoimmune diseases and compare with those of healthy individuals of similar age. The metalloproteinase content was analyzed by zymography and it was found that the serum levels of metalloproteinase-2 and metalloproteinase-9 of all autoimmune disease samples were decreased, in all diseases examined and independently of clinical activity, while those of active metalloproteinase-9 were significantly elevated. Both tissue inhibitors were quantitated by direct enzyme-linked immunosorbent assay and were also found decreased in autoimmune disease samples, confirming the balance that should exist in the secretion of metalloproteinases and tissue inhibitors. These results suggested that the increased active form of metalloproteinase-9, together with the decreased concentration of tissue inhibitor-2, could be used for diagnostic purposes and for the follow-up of patients with autoimmune diseases.

Keywords: ageing; enzymes; osteoarthritis; rheumatoid arthritis

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

N. Ziouti, N.S. Mastronikolis, A.P. Andonopoulos, C.D. Georgakopoulos, and D.H. Vynios
Analytical Biochemistry, 2006, Volume 350, Number 1, Page 159
Chris C. Woods, Krishnan Sundar, Cynthia Tessler, Ty W. Lebsack, Lora Grainger, Alma Nielsen, David Bleich, and Dominick DeLuca
Journal of Autoimmunity, 2006, Volume 27, Number 1, Page 28

Comments (0)

Please log in or register to comment.